Q4 2025 MDxHealth SA Earnings Call Transcript
Key Points
- MDxHealth SA (MDXH) reported a 19% increase in revenues for Q4 2025, reaching $29.5 million compared to $24.7 million in the prior year quarter.
- The company achieved a 62% total unit growth in test volumes, with liquid-based tests increasing by 128% year-over-year.
- Gross profit for the quarter increased by 20% to $18.7 million, with gross margins improving to 63.2%.
- MDxHealth SA successfully integrated the exoDX business, transitioning all select MDX customers to exoDX, which is expected to enhance operating efficiencies.
- The company has a strong focus on customer experience, achieving a best-in-class turnaround time of 5 days or less for critical tissue-based patient samples.
- MDxHealth SA's operating loss for Q4 2025 increased by 14% to $5.3 million, primarily due to higher headcount and operating expenses from the exoDX acquisition.
- Net loss for the quarter rose by 31% to $8.9 million, driven by increased net financial expenses.
- Adjusted EBITDA for Q4 was negative $2.1 million, compared to negative $1.4 million in the same quarter of 2024.
- The company's cash and cash equivalents stood at $29 million as of December 31, 2025, indicating potential cash flow challenges.
- There was a $1 million adjustment to the pre-release revenue estimate due to complexities in closing processes following the exoDX acquisition.
Good day and welcome to the MDxHealth Fourth quarter and full year 2025 earnings conference call. (Operator Instructions) I would now like to turn the conference over to John Francis with LifeSci Advisors. Please go ahead.
Before we begin, I'd like to remind everyone that the company will make forward-looking statements during today's call.
Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factors section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20.
I'll now turn the call over to Michael McGarrity, Chief Executive Officer.
Thanks, John.
And thank you all for joining us for our 4th quarter and full year 2025 earnings conference call for MDX Health.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
